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Colorectal cancer is one of the most common cancers in the world, and it is one of
the leading causes of cancer-related death. Despite recent progress in the development
of screening programs and in the management of patients with colorectal cancer,
there are still many gaps to fill, ranging from the prevention and early diagnosis to the
determination of prognosis factors and treatment of metastatic disease, to establish
a personalized approach. The genetic profile approach has been increasingly used
in the decision-making process, especially in the choice of targeted therapies and
in the prediction of drug response, but there are still few validated biomarkers of
colorectal cancer for clinical practice. The discovery of non-invasive, sensitive, and
specific biomarkers is an urgent need, and translational proteomics play a key role in this
process, as they enable better comprehension of colorectal carcinogenesis, identification
of potential markers, and subsequent validation. This review provides an overview of
recent advances in the search for colorectal cancer biomarkers through proteomics
studies according to biomarker function and clinical application.
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INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed cancer among adults and is
the third leading cause of cancer-related death in the United States (1). Most colorectal cancers
occur sporadically and are characterized by a sequenced carcinogenesis process that involves the
progressive accumulation of mutations in a period that lasts on average 10–15 years (2–5). This
long evolution interval allows for the successful application of screening, early detection of cancer,
and removal of premalignant lesions (adenomas), leading to a reduction in incidence and mortality
(5–8). Despite the opportunity for early diagnosis, ∼20–25% of CRC cases are diagnosed at stage
IV, when the patients have already presented with distant metastasis and the 5-year survival rate
is <10%. In contrast, the 5-year survival for patients with early localized disease, when surgical
resection is possible, may be as high as 90% (9, 10).
The current gold standard screening strategy is through a colonoscopy. The guidelines
recommend that individuals aged 45 years and older with an average risk of CRC undergo regular
screening (8). However, colonoscopies have poor patient compliance. The procedure is expensive
and invasive and carries risks, such as hemorrhage, colonic perforation, and cardiorespiratory
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complications. Other reasons for low adherence are related
to a preoccupation with pudency, procedure discomfort, and
bowel preparation (11). The most frequently used non-invasive
screening method is the guaiac fecal occult blood test (gFOBT),
based on the identification of hemoglobin peroxidase activity in
the stool. Although FOBT is an easy and cost-effectivemethod for
screening CRC, it has relatively poor selectivity and sensitivity,
resulting in high rates of both false positives and false negatives
(4, 5).
Therefore, alternative cost-effective, non-invasive, easily
measurable, and accurate screening procedures are urgently
required for CRC screening. Thus, the clinical applications of
biomarkers in CRC are not only needed for the early detection
of the disease but are also essential for prognostic stratification,
surveillance, and therapy selection (Figure 1) (12–14). The
increasing emergence of adjuvant and neoadjuvant therapy
approaches results in an urgent need for predictive biomarkers
that guide the decision-making process (12). An example of the
importance of predictive biomarkers is how treatment with drugs
can antagonize the epidermal growth factor receptor (EGFR)
in patients with KRAS-wild-type tumors. The discovery of this
targeting therapy made the determination of KRAS status a
mandatory step for the adequacy of chemotherapy in patients
with advanced colorectal cancer (15).
Recent progress in genomics, transcriptomics, proteomics,
and metabolomics has expanded the number of candidate
biomarkers and led to better comprehension of the progression
of colorectal cancer as well as the identification of molecular
signatures (16–22).
Dysplastic and neoplastic tissues regulate the expression of
proteins and generate protein profiles that may be associated with
the progression of these lesions in many different and interacting
signaling pathways (23). Proteomics represents a large number of
approaches employed for large-scale recognition, measurement,
characterization, and analysis of proteins. The majority of studies
on biomarker discovery employ quantitative mass spectrometry-
based techniques for the identification and validation of
dysregulated proteins as disease biomarker candidates (24).
FIGURE 1 | Example of hypothetical application of translational proteomic research in colorectal cancer approach. The prospection of new predictive biomarkers is
cardinal to the implementation of an integrative and personalized medicine, making possible the individual assessment of targeted therapies, and drug response.
Translational proteomics research emphasizes the translation
of general proteomics science to determine protein expression
profiles that generate pathogenic phenotype variations and
contribute to clinical practice (15).
This review aims to provide an overview of recent advances
in mass spectrometry-based proteomics in the search for
protein biomarkers of CRC with the potential for clinical
application according to biomarker functions: diagnostic,
predictive, or prognostic.
DIAGNOSTIC BIOMARKERS
A diagnostic biomarker can be defined as a biological
characteristic that detects or suggests the presence of a disease
or condition of interest or identifies an individual with a subtype
of the disease (25).
It is well-established that colorectal cancer screening strategies
that lead to the identification and removal of adenomatous polyps
and other premalignant lesions result in a decrease in CRC
mortality (26). Colonoscopies are the only screening method
that can identify and remove precancerous polyps; however, the
exam requires bowel preparation and dietary modification, it
is operator dependent, and it has been associated with major
complications, such as cardiopulmonary events, gastrointestinal
bleeding, and perforation (27). Perforation is the most frequent
major complication, occurring in 0.016–0.8% of diagnostic
examinations and up to 5% of therapeutic colonoscopies (28).
Some studies report the non-attendance rate of colonoscopies
to be 10–20% after a positive fecal occult blood test (29, 30). The
main factors associated with non-adherence with colonoscopies
are laxative bowel preparation, lack of awareness of the
significance of screening, and concerns about embarrassment,
modesty, and dignity (31). Plumb et al. (32) evaluated the
explanations for colonoscopy non-participation, and ∼30% of
the patients addressed the unwillingness to undergo the test as the
major barrier to go through with the whole screening program.
Non-invasive methods such as fecal immunochemical tests,
gFOBT, and stool DNA tests can be used for regular screening,
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but positive results should be followed up with timely
colonoscopy (8). The current fecal occult blood test methods
are more easily accepted by participants in population screening
programs; however, they are subject to various interfering factors
with some causes of false-negative, false-positive results, and low
sensitivity rates for detecting colon polyps (33–35) Therefore,
early, non-invasive, specific, and sensitive biomarkers are still
required for screening strategies in colorectal cancer.
Many proteomic approaches have been used in the search
for potential diagnostic biomarkers. Ghazanfar et al. (36)
performed two-dimensional gel electrophoresis coupled with
mass spectrometry for the expression profiling of proteins
extracted from freshly frozen human colorectal cancer tissue
specimens (12 patients) and neighboring non-tumor tissue, and
they demonstrated the upregulation of some proteins, such as
actin beta-like 2 (ACTBL2), in colorectal cancer. Hao et al.
(37) used high-resolution Fourier transform mass spectrometry
to evaluate 22 pairs of cancerous and adjacent normal tissue
specimens that were gathered from 22 individuals and revealed
an overexpression of dipeptidase 1 (DPEP1) in colorectal
tumor tissue.
Formalin-fixed paraffin-embedded (FFPE) tissues can also
be used in proteomics approaches, allowing access to archival
samples, allowing usage of larger cohorts and more robust
analyses, and optimizing the follow-up data of patients’ clinical
conditions. Quesada-Calvo et al. (23) analyzed 76 formalin-
fixed paraffin-embedded colorectal tissues from early CRC stages
(pT1N0M0 and pT2N0M0), as well as normal or inflamed
mucosa, by label-free proteomics, and different expression levels
of olfactomedin-4 (OLFM4), kininogen-1 (KNG1), and transport
protein Sec24C (Sec24C) were observed in the early CRC stages
compared to normal and premalignant tissues. Although the
experiment was performed with liquid chromatography-mass
tandem mass spectrometry (LC-MS/MS), the results were also
validated by immunohistochemistry of these annotated effectors.
Yamamoto et al. (38) also used formalin-fixed and paraffin-
embedded (FFPE) CRC tissue to perform liquid chromatography
(LC)/mass spectrometry (MS) based on a global proteomic
approach, revealing higher expression levels of cyclophilin A,
annexin A2, and aldolase A in cancer compared to non-cancer
regions (38).
Blood-based biomarkers are potentially the best matrices for
early diagnosis and surveillance of colorectal cancer because the
specimens can be obtained easily by a non-invasive method with
minimal cost and risk (24, 39). Ivancic et al. (40) used targeted
liquid chromatography-tandem mass spectrometry to analyze
blood from 213 healthy individuals and 50 patients with non-
metastatic CRC. This approach resulted in a panel of five proteins
(leucine-rich alpha-2-glycoprotein 1, EGFR, inter-alpha-trypsin
inhibitor heavy-chain family member 4, hemopexin, and
superoxide dismutase 3) with good performance for CRC
detection, which present 89% specificity at over 70% sensitivity
in the validation set. Bhardwaj et al. (41) also proposed a protein
panel for the early detection of CRC, utilizing an approach
with liquid chromatography/multiple reaction monitoring-mass
spectrometry and a subsequent proximity extension assay to
analyze plasma from 96 CRC patients and 94 controls. They
demonstrated promising CRC-screening performance of a five-
marker blood-based profile consisting of mannan binding lectin
serine protease 1, osteopontin, serum paraoxonase lactonase 3,
transferrin receptor protein 1, and amphiregulin.
Yu et al. (42) used magnetic beads and matrix-assisted
laser-desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry to analyze 127 CRC serum samples and 90 healthy
control serum samples. The protein serine/threonine kinase 4
(STK4 or MST1) was identified by tandem mass spectrometry
(MS/MS) and validated with Western blotting and an enzyme-
linked immunosorbent assay (ELISA). They demonstrated a
downregulation of MST1 in CRC patients, with a sensitivity of
92.3% and specificity of 100% in the diagnosis of colorectal cancer
when gathered with carcinoembryonic antigen and FOBT. Their
work also implied that MST1 could be a predictive marker for
distant metastasis (42).
Fan et al. (43) also conducted a study with serum samples
that were analyzed by a combination of high-performance
liquid chromatography and mass spectrometry and further
validation with Western blotting. They verified an upregulation
of macrophage mannose receptor 1 (MRC1) and S100 calcium-
binding protein A9 (S100A9) in colorectal cancer. Members
of the serpin family, such as SERPINA1 (alpha-1-antitrypsin,
A1AT), SERPINA3 (alpha-1-antichymotrypsin, AACT), and
SERPINC1 (antithrombin-3, AT-III), have also been described
as potential biomarkers of adenomatous polyps and colorectal
carcinomas through analyses of serum samples by multiplexed
quantification with an isobaric tag for relative and absolute
quantitation (iTRAQ) (44).
Despite the expansion of MS-based proteomics research and
the large number of diagnostic biomarker candidates (Table 1
shows some examples of candidates for diagnostic protein
biomarkers), none of them were successfully translated into
clinical practice. This probably occurs due to the difficulty
of validating the possible biomarkers in large cohorts and
comparing the results with the current screening methods.
However, the continuation of proteomic research is essential
because, certainly, there is a space in the CRC screening that
needs to be filled by reliable biomarkers.
PREDICTIVE BIOMARKERS
The predictive biomarkers are used to indicate the response to
a specific treatment and to guide the decision-making process.
The prospection of new predictive biomarkers is crucial to the
evolution of themanagement of patients with colorectal cancer in
the near future, and proteomics represent a powerful strategy for
the discovery and implementation of personalized approaches.
The increasing number of chemotherapy and immunotherapy
drugs and the emergence of target therapies make it necessary to
discover some response parameters and monitoring evaluations
(45, 46).
Concerning the individualized and integrative treatment
of patients with colorectal cancer, the understanding of
the mechanism underlying chemotherapy resistance is a
prerequisite to overcome the resistance and improve the efficacy
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TABLE 1 | Examples of candidate diagnostic biomarkers.
References Biomarker/Regulation Technique Sample
Ghazanfar et al. (36) - Actin beta-like 2 (ACTBL2) Two-dimensional gel electrophoresis coupled to mass
spectrometry (2DE-MS)
CRC tissue
Hao et al. (37) - Dipeptidase 1 (DPEP1) Fourier transform mass spectrometry (FTMS) CRC tissue
Quesada-Calvo et al. (23) - Olfamectomedin-4 (OLFM4)
- Kininogen-1 (KNG1)
- Transport protein Sec-24 (Sec-24)
Liquid chromatography–mass spectrometry (LC-MS). Further
immunohistochemistry validation.
FFPE CRC tissue
Yamamoto et al. (38) - Cyclophilin A
- Annexin A2
- Aldolase A
LC-MS FFPE CRC tissue
Ivancic et al. (40) - Leucine-rich alpha-2-glycoprotein 1Epidermal
growth
- factor receptor
- Inter-alpha-trypsin inhibitor heavy-chain family
member 4
- Hemopexin
- Superoxide dismutase 3
Targeted liquid chromatography-tandem mass spectrometry Serum
Bhardwaj et al. (41) - Mannan binding lectin serine protease 1
- Osteopontin
- Serum paraoxonase lactonase 3
- Transferrin receptor protein 1
- Amphiregulin
Liquid chromatography/multiple reaction monitoring-mass
spectrometry and proximity extension assay
Plasma
Yu et al. (42) - Serine/threonine kinase 4 (STK4 or MST1) Mass spectrometry (MS/MS). Also verified with Western blotting
and enzyme-linked immunosorbent assay (ELISA).
Serum
Fan et al. (43) - Macrophage mannose receptor 1 (MRC1)
- S100 calcium-binding protein A9 (S100A9)
High-performance liquid chromatography (HPLC) and Western
blotting.
Serum
Peltier et al. (44) - Alpha-1-antitrypsin (SERPINA 1)
- Alpha-1 antichymotrypsin (SERPINA 3)
- Antithrombin-3 (SERPINC1)
Multiplexed quantification with isobaric tag for relative and
absolute quantitation (iTRAQ)
Serum
of chemotherapy. In addition, the identification of good-
responder patients is also important to guide and improve
personalized therapies. Wang et al. (47) correlated the capacity
of proteomic, genomic, and transcriptomic profiles to predict
drug sensitivity. Forty-four CRC cell lines were analyzed by liquid
chromatography-tandemmass spectrometry (LC-MS/MS)-based
shotgun proteomics and compared against 90 colorectal cancer
primary tumor specimens and 60 normal tissue biopsies. The
proteomic profile was compared on mutations, DNA copy
number, and mRNA expression, and the results showed that
proteomic data tended to exhibit better potential for predicting
sensitivity to 5-fluorouracil, SN-38, erlotinib, regorafenib, and
oxaliplatin when compared to genomic and transcriptomic
profiles (47).
Guo et al. (48) investigated protein elements that might
be implicated in oxaliplatin resistance by comparing the
proteome between oxaliplatin-sensitive HT-29 wild-type cells
and oxaliplatin-resistant HT-29 cells using 2D gel electrophoresis
followed by MALDI TOF/TOF mass spectrometry. It was
observed that poly(C)-binding protein 1 (PCBP1) expression was
significantly more elevated in tumor samples from oxaliplatin-
refractory patients than in those from responsive patients,
suggesting that PCBP1 is a protein marker of oxaliplatin
resistance in colorectal cancer cell cultures.
Martin et al. (49) evaluated the response to vascular
endothelial growth factor inhibitor (bevacizumab) in patients
with metastatic colorectal cancer through the analysis of
pretreatment serum from 23 patients. 2D difference gel
electrophoresis (2D-DIGE) was performed, followed by LC-
MS/MS, which identified 68 differentially expressed proteins
between responders and non-responders. Three proteins,
apolipoprotein E (APOE), angiotensinogen (AGT), and vitamin
D-binding protein (DBP), were chosen for validation through
immunohistochemistry and enzyme-linked immunosorbent
assay (ELISA) and were correlated with better survival outcomes
in patients treated with chemotherapy and bevacizumab (49).
The response to EGFR-targeted therapies was also evaluated
by Katsila et al. (50) through a quantitative proteomic analysis
of the plasma of patients with metastatic colorectal cancer
compared with the 3D colorectal cancer spheroid secretome
(isogenic cells SW48) of patients treated with cetuximab. They
showed that the plasma level of phosphorylated-EGFR (pEGFR)
was associated with sensitivity to cetuximab therapy, suggesting
that pEGFR could be a predictive drug-response biomarker (50).
An expanding research area due to tailored-made therapy
for patients with colorectal cancer is the therapeutic targets in
anti-tumor immunity (51). Studies with immune checkpoint-
inhibiting drugs, such as those directed against cytotoxic
T-lymphocyte antigen 4 (CTLA-4) and programmed death-
1 receptor (PD1) and its ligand PD-L1, have demonstrated
promising results in the therapy of patients with metastatic
colorectal cancer (52–54).
Frontiers in Oncology | www.frontiersin.org 4 November 2019 | Volume 9 | Article 1284
Alves Martins et al. Translational Proteomics in Colorectal Cancer
Until now, the best indicator of responsiveness to
immunotherapy in patients with colorectal cancer seems to
be mismatch repair deficiency (55). Repair system deficiency
leads to a high burden of somatic mutations, which increases the
immunogenicity (51).
Furthermore, tumors with high microsatellite instability
(MSI-H) present a dense Th1 lymphocytic infiltration and a
cytokine-rich microenvironment that is related to the highly
upregulated expression of multiple immune checkpoint proteins
(56). Unfortunately, the patients with MSI-H tumors represent
only a subgroup of the patients with colorectal cancer, and the
likelihood of mismatch repair deficiency varies according to the
stage of the disease, reaching 4–5% in the metastatic disease.
In addition, not all patients with MSI-H tumors respond to
immunotherapy (57).
Therefore, a complete understanding of the response of
the immune system to MSI-H is crucial to optimizing the
immunotherapy approach. Some studies have demonstrated
promising prognostic biomarkers, such as the expression of
heat shock protein 110 and protein ß2-microglobulin, to stratify
patients with MSI-H CRC according to prognosis (58, 59).
In this scenario, the application of mass spectrometry-based
immune-proteomic methods is a powerful tool in the search for
overexpressed immunogenic proteins that could be new targets
of immunotherapeutic development. Yang et al. (60) used mass
spectrometry to evaluate antibody-reactive proteins, and this
was followed by Western blotting and immunohistochemistry
validation. Their experiment described differential expression of
proteasome subunit alpha type 1 (PSA1), leucine aminopeptidase
3 (LAP3), annexin A3 (ANXA3), and maspin (serpin B5),
demonstrating a proteomic profile of antibody-inducing cancer-
associated immunogens (60). In another study with an immuno-
proteomic approach by the same group, overexpression of
olfactomedin 4, CD11b, and integrin alpha-2 was identified in
the tumor tissue of patients with colorectal cancer with liver
metastases (61).
The current treatment of locally advanced rectal cancer (stages
II and III) is neoadjuvant chemoradiation followed by surgery
(62). The main role of neoadjuvant therapy is local tumor
control, but, in ∼10–20% of patients, a pathologic complete
response is observed. This fact allows for the possibility of
a selective surgical approach, which was described in Habr-
Gama et al. (63). One of the most challenging issues in
the modern management of patients with rectal cancer is
to predict the response to neoadjuvant therapy. Recently,
Chauvin et al. (64) highlighted different protein signatures in
patients who underwent neoadjuvant therapy in a study on
mass spectrometry of formalin-fixed paraffin-embedded tumor
biopsies. The researchers identified that interferon-induced
protein with tetratricopeptide repeats 1 (IFIT1), FAST kinase
domains 2 (FASTKD2), phosphatidylinositol-5-phosphate 4-
kinase type-2 beta (PIP4K2B), AT-rich interactive domain-
containing protein 1B (ARID1B), and solute carrier family
25 member 33 (SLC25A33) were overexpressed in the tumor
tissue of the initial biopsy from patients who achieved complete
response to neoadjuvant chemoradiotherapy. In the non-
responder group, they identified that caldesmon 1 (CALD1),
carboxypeptidase A3 (CPA3), beta-1,3-galactosyltransferase 5
(B3GALT5), CD177, and receptor-interacting serine/threonine-
protein kinase 1 (RIPK1) were overexpressed (64).
The predictive protein biomarkers face the same problem
of slow translation to clinical application as the diagnostic
biomarkers. Table 2 shows some examples of candidates
for predictive protein biomarkers. The pursuit for new
biomarkers maintains a central role in the development of the
integrative management of CRC patients because it is crucial to
determine the responses to neoadjuvant and adjuvant therapies.
Mass spectrometry’s ability to detect low-abundance elements
makes this technique a powerful tool for prospecting these
potential biomarkers.
PROGNOSTIC BIOMARKERS
A prognostic biomarker can be defined as a biological
characteristic that gives information about the patient’s overall
cancer outcome, independent of therapy (65). The current
staging strategy for colorectal cancer is the TNM system, which
consists of the analysis of tumor depth of invasion (T), nodal
involvement (N), and presence of metastasis (M) (66). The
overall prognosis is determined by a combination of clinical
and pathologic variables; however, the prognosis can be different
between patients in the same stage, and, in some cases, patients
at early stages can present poorer outcomes than patients at
advanced stages. These variations are the result of a complex
process of colorectal carcinoma (CRC) pathogenesis that involves
multistep molecular pathways, initiated by genetic and epigenetic
events (19).
The main prognostic biomarker used in clinical practice
is carcinoembryonic antigen (CEA), a high-molecular-weight
glycoprotein expressed in embryonic tissue and colorectal
malignancies. This antigen was discovered in 1965, but it remains
the most widely used blood-based biomarker for CRC. Elevated
levels are associated with cancer progression and can indicate
recurrence after surgery. However, high CEA levels are not
specific to CRC and can also be found in other malignancies and
inflammatory conditions, such as inflammatory bowel disease,
liver disease, and pancreatitis (67, 68).
Recently, other parameters have been used to determine the
prognosis. The effect of microsatellite instability (MSI) and BRAF
mutation on survival in colorectal carcinoma was elucidated,
and these genetic markers already have clinical applications (19).
Despite these recent advances, additional prognostic biomarkers
are urgently needed to optimize the management and follow-up
of colorectal cancer patients.
The presence of metastases represents the main unfavorable
prognostic factor in patients with colorectal cancer. The
estimated 5-year survival for stage IV patients is ∼8% (69). The
major site of metastases in colorectal cancer is the liver, occurring
in 20–35% of patients at the time of diagnosis and in nearly 70%
of patients during the course of the disease (70). Marfà et al.
(71) used a high-throughput proteomic technique to predict 5-
year survival in patients with colorectal cancer who developed
liver metastases. Human hepatic tumor samples were analyzed
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TABLE 2 | Examples of candidate predictive biomarkers.
References Biomarker Relevance Technique Sample




Martin et al. (49) - Apolipoprotein E 180 (APOE)
- Angiotensinogen (AGT)
- Vitamin D binding protein (DBP)
Survival outcomes in patients
treated with bevacizumab
Gel electrophoresis (2D-DIGE), followed by
LC-MS/MS
Serum
Katsila et al. (50) - Phosphorylated EGFR (pEGFR) Response to Cetuximab Quantitative proteomic analysis Plasma
Yang et al. (60) - Proteasome subunit alpha type 1 (PSA1
- Leucine aminopeptidase 3 (LAP3)
- Annexin A3 (ANXA3)





Mass spectrometry to evaluated




Chauvin et al. (64) - Interferon induced protein with
tetratricopeptide repeats 1 (IFIT1)
- FAST Kinase Domains 2 (FASTKD2)
- Phosphatidylinositol-5-phosphate 4-kinase
type-2 beta (PIP4K2B)
- AT-rich interactive domain-containing protein
1B (ARID1B)
- Solute carrier family 25 member 33
(SLC25A33)
- Caldesmon 1 (CALD1)
- Carboxypeptidase A3 (CPA3)







Mass spectrometry FFPE CRC tissue
by surface-enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI), and a classification and regression
tree analysis was done posteriorly. This approach allowed the
identification of four relevant protein peaks and the construction
of an algorithm that revealed an excellent diagnostic accuracy
in differentiating mild from severe colorectal liver metastases
patients (71).
Recently, Kirana et al. (72) performed a combination of laser
microdissection, 2D-DIGE and MALDI-TOF MS to identify
proteins associated with colorectal cancer spread. Initially,
laser microdissection was applied to isolate cancer cells from
primary colorectal tumors of stage II patients in two distinct
groups: (i) patients who presented metastases within 5 years
of initial surgical intervention and (ii) patients who did not
present metastases within 5 years of initial surgical intervention.
Then, 2D-DIGE (a technique that uses fluorescent dyes to label
different conditions) and MALDI-TOF were used to identify
the global profile of proteins, with posterior validation achieved
through tissue microarray (TMA) immunohistochemistry.
The expression of HLAB, 14-3-3β protein, a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS2),
latent transforming growth factor beta binding protein 3
(LTBP3), nucleoside diphosphate kinase 2 (NME2), and jagged
2 protein (JAG2) was associated with clinical pathological
parameters related to tumor progression, invasion, and
metastasis (72).
Zhu et al. (73) used another approach, based on magnetic
bead-based fractionation coupled with mass spectrometry, to
compare serum samples from patients with metachronous
liver metastases vs. patients without recurrence or metastases
for at least 3 years after radical colorectal surgery. Serum
proteomic fingerprinting was done, and it exhibited a
promising value for predicting metachronous liver metastases
in patients who underwent radical resection of colorectal
cancer. The peptides were recognized as fragments of alpha-
fetoprotein, complement C4-A, fibrinogen alpha, eukaryotic
peptide chain release factor GTP-binding subunit ERF3B, and
angiotensinogen (73).
The collagen proteins seem to be promising candidates as
biomarkers in the metastatic scenario of colorectal cancer. A
recent MS-based proteomic approach compared colorectal
liver metastasis tissues with healthy adjacent liver tissues,
demonstrating the upregulation of 19 of 22 collagen-α chains
in colorectal liver metastasis tissue. Posterior validation with
immunohistochemistry showed significant upregulation of
collagen type XII in the metastatic context (74).
Some studies have also demonstrated the possibility of
detecting colorectal liver metastases through the identification
of collagen peptides in urine (75, 76). Urine is an interesting
potential source of biomarkers as this biological fluid is easy
to obtain non-invasively (24). An example of a promising
application of this method is the measurement of the urinary
prostaglandin metabolite PGE-M. PGE-M is the major urinary
metabolite of prostaglandin E2, which plays an important
role in mediating the effects of cyclooxygenase-2 in colorectal
carcinogenesis. Elevated urinary levels of PGE-M seem to be
correlated with advanced adenomas and an elevated risk of
colorectal cancer (77–81).
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The determination of nodal status in CRC is another point
that requires new candidate prognostic biomarkers. Lymph
node involvement results in poor prognosis, reducing the 5-
year survival rate from 70 to 80% in patients with node-
negative disease to 30%−60% in those with node-positive
disease (82). The current non-invasive imaging methods used
for the preoperative detection of lymph node metastasis, such
as computed tomography, magnetic resonance imaging, and
endorectal ultrasound, have low accuracy rates (83).
Non-invasive methods to predict the nodal status could
improve the management of patients with colorectal cancer,
guiding the indication of chemotherapy or the extension
of the surgery. Mori et al. (84), in a recent study, used
isobaric tags for relative and absolute quantitation (iTRAQ)
as part of a proteomic analysis that identified 60 differentially
expressed proteins specifically related to lymph node metastasis
in patients with colorectal cancer. The validation process by
immunohistochemistry revealed that heat shock protein 47
(HSP47) expression in colorectal cancer tissue was significantly
higher than in adjacent normal colonic mucosa (84).
In another study by the same group, iTRAQ was used in
a comparative proteomics approach, demonstrating that a high
level of ezrin protein was an independent predictor of lymph
nodemetastasis in colorectal cancer (85). The ezrin protein seems
to occupy an important place in the carcinogenesis process,
being described as a biomarker candidate for the progression
and prognosis of gastrointestinal cancers and a target for anti-
metastatic therapy (86, 87). Furthermore, some studies associate
the upregulation of ezrin expressionwith rectal cancer recurrence
and tumor aggressiveness (88, 89).
One of the most concerning points in the postoperative
follow-up of CRC is recurrence detection. After surgery with
curative intent, 30–40% of the patients present locoregional
recurrence or distant metastasis (90). Regarding the discovery
of prognostic biomarkers of colorectal cancer recurrence, Clarke
et al. (91), in a recent study, used a reverse phase protein
array to unveil the functional proteome in 263 colorectal cancer
tumor samples from patients treated at MD Anderson Cancer
Center and 462 primary tumor tissue from The Cancer Genome
Atlas archived colorectal tumor bank. On multivariate analysis,
eight proteins demonstrated significant prognostic factors for
tumor recurrence: collagen VI, forkhead box O3, inositol
polyphosphate-4-phosphatase, LcK tyrosine kinase, phospho-
PEA15 (Ser116), phospho-PRAS40, Rad51, and phospho-S6
(Ser240-244) (91).
The expression of maspin was also described as a marker
for early recurrence in stage IV colorectal cancer. Snoeren
et al. (92) analyzed tumor tissue samples from five stage IV
patients with early recurrence (<6 months) and five patients
with prolonged time to recurrence (>24 months) through mass
spectrometry with subsequent validation by Western blotting.
They demonstrated that maspin was differentially expressed in
stage IV colorectal cancer patients with early and late recurrence
after surgery for colorectal liver metastases (92).
Despite the cited potential prognostic biomarkers (Table 3),
carcinoembryonic antigen remains the only established protein
TABLE 3 | Examples of candidate prognostic biomarkers.
References Biomarkers Technique Sample
Kirana et al. (72) - HLAB
- 14-3-3β protein
- Disintegrin and metalloproteinase with thrombospondin
motifs (ADAMTS2)
- Latent transforming growth factor beta binding protein 3
(LTBP3)
- Nucleoside diphosphate kinase 2 (NME2)
- Jagged 2 protein (JAG2)
Combination of laser microdissection, 2D-DIGE and
MALDI-TOF MS, with posterior validation through tissue
micro array (TMA) immunohistochemistry.
CRC tissue
Zhu et al. (73) - Fragments of alpha-fetoprotein
- Complement C4-A
- Fibrinogen alpha
- Eukaryotic peptide chain release factor GTP-binding
subunit ERF3B
- Angiotensinogen
Magnetic bead-based fractionation coupled with MS. Serum
Van Huizen et al. (74) Collagen type XII Mass-spectrometry Colorectal liver
metastasis tissues
Mori et al. (84) Heat shock protein 47 (HSP47) iTRAQ with validation by immunohistochemistry Tumor tissue
Mori et al. (85) Ezrin protein iTRAQ Tumor tissue
Clarke et al. (91) - Collagen VI
- Forkhead box O3
- Inositol polyphosphate-4-phosphatase




Reverse phase protein lysate microarray
(RPMA)
Tumor tissue
Snoeren et al. (92) Maspin MS, with subsequent validation by Western blotting Tumor tissue
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biomarker in clinical practice to determine prognosis. The
identification, validation, and translation of new prognostic
biomarkers is important to fill the presented gaps in our
knowledge, such as the prediction of nodal status, distance
metastasis, and postsurgical recurrence.
CONCLUSION
The approach to patients with colorectal cancer has been
dramatically updated recently thanks to a better understanding
of the process of carcinogenesis and advances in the field of
genetics. The determination of KRAS, BRAF, and MSI status
has become an indispensable step in therapeutic planning,
especially in patients with metastatic disease. Furthermore,
the emergence of immunotherapy and the increasing use of
liquid biopsies have extended the possibilities in the decision-
making process toward personalized medicine. However, even
with these advances, there is a lack of biomarkers that can
guide the early diagnosis or the targeted treatment, prognosis,
and surveillance of patients with colorectal cancer. Despite
the improvements in MS technologies and the large number
of proteomics-based studies to find biomarkers, this approach
is not mainstream, especially regarding the management of
colorectal cancer patients. This difficulty in translating protein
markers into clinical practice is probably due to the small sample
sizes of studies and to the heterogeneity in the processes of
sample obtainment, preparation, and storage. These factors,
coupled with complexities of data analysis and interpretation
of proteomic approaches, result in poor reproducibility of
the studies. However, the greatest limitation is related to the
absence of validation of the possible biomarkers in large cohorts,
comparing the data with the current methods of diagnosis,
prediction, and prognosis. In this scenario, translational
proteomics remains a powerful and promising tool for the
discovery of biomarkers that can lead to important changes in
the management of patients with colorectal cancer. Probably,
the key to personalized medicine in colorectal cancer relies
on studies that can integrate genomic, transcriptomic, and
proteomic data, from amultiomics point of view, in the search for
a biomarker panel that combines strong clinical data and accurate
molecular findings.
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